Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L. Egeler M, et al. Among authors: van leeuwen m, van houdt w, van de poll franse l, van akkooi a. Eur J Cancer. 2024 Mar;200:113601. doi: 10.1016/j.ejca.2024.113601. Epub 2024 Feb 4. Eur J Cancer. 2024. PMID: 38340383
Conditional survival of malignant melanoma in The Netherlands: 1994-2008.
van der Leest RJ, van Steenbergen LN, Hollestein LM, de Vries E, Nijsten T, van Akkooi AC, Janssen-Heijnen ML, Coebergh JW. van der Leest RJ, et al. Eur J Cancer. 2014 Feb;50(3):602-10. doi: 10.1016/j.ejca.2013.10.019. Epub 2013 Nov 18. Eur J Cancer. 2014. PMID: 24262585
Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria.
Madu MF, Franke V, Bruin MM, Berger DMS, Bierman C, Jóźwiak K, Klop WMC, Wouters MWJM, van Akkooi ACJ, Van de Wiel BA. Madu MF, et al. Among authors: van akkooi acj, van de wiel ba. Eur J Cancer. 2017 Dec;87:212-215. doi: 10.1016/j.ejca.2017.09.002. Epub 2017 Oct 3. Eur J Cancer. 2017. PMID: 28986137 No abstract available.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Eggermont AMM, et al. Among authors: van akkooi acj, van den eertwegh ajm. N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15. N Engl J Med. 2018. PMID: 29658430 Free article. Clinical Trial.
Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.
Verver D, van Klaveren D, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, Testori A, van Leeuwen BL, van der Veldt AAM, Keilholz U, Eggermont AMM, Verhoef C, Grünhagen DJ. Verver D, et al. Among authors: van klaveren d, van akkooi acj, van der veldt aam, van leeuwen bl. Eur J Cancer. 2018 Jun;96:25-33. doi: 10.1016/j.ejca.2018.02.022. Epub 2018 Apr 13. Eur J Cancer. 2018. PMID: 29660597
246 results